Eric Swayze Sells 10,602 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 10,602 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $79.18, for a total value of $839,466.36. Following the transaction, the executive vice president directly owned 21,759 shares in the company, valued at approximately $1,722,877.62. This trade represents a 32.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ionis Pharmaceuticals Stock Performance

IONS opened at $81.18 on Friday. Ionis Pharmaceuticals, Inc. has a 12-month low of $39.37 and a 12-month high of $86.74. The stock has a market cap of $13.42 billion, a price-to-earnings ratio of -39.22 and a beta of 0.37. The business has a 50 day moving average of $75.03 and a 200-day moving average of $77.36. The company has a quick ratio of 4.09, a current ratio of 4.10 and a debt-to-equity ratio of 2.75.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.29. The company had revenue of $246.09 million during the quarter, compared to the consensus estimate of $195.56 million. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The firm’s revenue for the quarter was up 86.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.93) EPS. On average, equities research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.69 earnings per share for the current year.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Brown Brothers Harriman & Co. acquired a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at about $27,000. Cassaday & Co Wealth Management LLC acquired a new stake in Ionis Pharmaceuticals in the 1st quarter worth about $30,000. Quarry LP bought a new stake in Ionis Pharmaceuticals in the 3rd quarter valued at about $38,000. Johnson Financial Group Inc. bought a new stake in Ionis Pharmaceuticals in the 3rd quarter valued at about $44,000. Finally, Laurel Wealth Advisors LLC acquired a new position in shares of Ionis Pharmaceuticals during the 4th quarter worth approximately $47,000. Institutional investors own 93.86% of the company’s stock.

Wall Street Analysts Forecast Growth

IONS has been the topic of several research analyst reports. Oppenheimer reissued an “outperform” rating and issued a $111.00 price objective on shares of Ionis Pharmaceuticals in a research report on Thursday, April 30th. Leerink Partners lifted their target price on shares of Ionis Pharmaceuticals from $122.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday. Citigroup started coverage on shares of Ionis Pharmaceuticals in a research note on Monday, May 18th. They issued a “buy” rating and a $115.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Tuesday, April 21st. Finally, Royal Bank Of Canada raised their price objective on shares of Ionis Pharmaceuticals from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Ionis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $102.90.

Key Stories Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Ionis received FDA approval expanding TRYNGOLZA to treat severe hypertriglyceridemia, strengthening the drug’s commercial opportunity and making it the first approved therapy for the condition. Article Title
• Positive Sentiment: Ionis announced a licensing deal with Recordati for ex-U.S. rights to zilganersen in Alexander disease, which provides upfront and royalty potential while allowing Ionis to keep U.S. commercialization rights. Article Title
• Positive Sentiment: Leerink Partners raised its price target on Ionis, signaling continued analyst confidence in the company’s pipeline and commercial execution. Article Title
• Neutral Sentiment: HC Wainwright kept a Buy rating but lowered some 2027 EPS estimates, which is a mild headwind but not a major shift in the firm’s overall view. Article Title

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.